In T-ALL, the PI3K/Akt pathway is commonly activated generating anti-apoptotic and proliferative signals [60,61,76] and, accordingly, this signaling pathway has been explored as a novel therapeutic target in T-ALL [77]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.